-
1 Comment
BioInvent International AB (publ) is currently in a long term downtrend where the price is trading 79.9% below its 200 day moving average.
From a valuation standpoint, the stock is 98.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.8.
BioInvent International AB (publ)'s total revenue sank by 9.9% to $16M since the same quarter in the previous year.
Its net income has increased by 11.4% to $-33M since the same quarter in the previous year.
Finally, its free cash flow fell by 32.1% to $-33M since the same quarter in the previous year.
Based on the above factors, BioInvent International AB (publ) gets an overall score of 2/5.
| Sector | Healthcare |
|---|---|
| Industry | Biotechnology |
| Exchange | F |
| CurrencyCode | EUR |
| ISIN | None |
| Market Cap | 7M |
|---|---|
| PE Ratio | None |
| Target Price | None |
| Dividend Yield | 0.0% |
| Beta | 0.91 |
BioInvent International AB (publ) focuses on the research and development of immunomodulating antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's lead drug candidate is BI-1206, a monoclonal antibody targeting CD32b, which is in Phase I/IIa clinical trials in patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia who are resistant to rituximab. It has a collaboration agreement with Oncurious to develop TB-403, which is in Phase I/II clinical trials used for the treatment of patients with medulloblastoma. The company is also developing immuno-modulatory antibodies, such as cancer-associated regulatory T cells for modulating the immune system and BI-1808, an antibody candidate. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumour-associated myeloid cells; and partnership and collaboration with Transgene to co-develop multi-functional oncolytic viruses for treatment of solid tumors. The company also has an agreement with SkylineDx to characterize the gene expression and immunological signatures in tumors of patients pre-and post-treatment with BI-1206. The Company was founded in 1996 and is based in Lund, Sweden.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for BIX.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
